Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.93 |
| ▸ | EYA2 | O00167 | 1/20 | 0.93 |
| ▸ | APP | P05067 | 1/20 | 0.93 |
| ▸ | ACE | P12821 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 2/20 | 0.88 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.88 |
| ▸ | TSHR | P16473 | 2/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.88 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.88 |
| ▸ | DRD1 | P21728 | 1/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.88 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.88 |
| ▸ | DRD3 | P35462 | 1/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.88 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL19553737 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL15136 | 0.97 | TDP1 (1.00) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8624198 | 0.97 | TDP1 (1.00) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8607480 | 0.97 | TDP1 (1.00) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL3035039 | 0.97 | TDP1 (1.00) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1373 | 0.97 | TDP1 (1.00) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL16714076 | 0.97 | TDP1 (1.00) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL625800 | 0.93 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL65334 | 0.93 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1396918 | 0.93 | TDP1 (0.93) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300781-B | Composite material, preparation method thereof and quantum dot light-emitting diode | TCL科技集团股份有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-112300781-A | Composite material, preparation method thereof and quantum dot light-emitting diode | TCL集团股份有限公司 | 2021-02-02 | — | — | CN | claimed |
| CN-111519219-A | Silver electroplating liquid composite additive and preparation method and application thereof | 东莞奕创表面处理科技有限公司 | 2020-08-11 | — | — | CN | claimed |
| EP-1809264-B1 | ANTIMICROBIAL AMORPHOUS COMPOSITIONS | AVENT INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-1912683-B1 | ANTIMICROBIAL COMPOSITION | ETHICON INC (US) | 2014-03-12 | — | — | EP | claimed |
| US-20110262556-A1 | SILVER/WATER, SILVER GELS AND SILVER-BASED COMPOSITIONS; AND METHODS FOR MAKING AND USING THE SAME | AMERICAN SILVER, LLC (US) | 2011-10-27 | — | — | US | claimed |
| US-20100074932-A1 | ANTIMICROBIAL COMPOSITIONS CONTAINING GALLIUM | C. R. BARD INC. | 2010-03-25 | — | — | US | claimed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | claimed |
| EP-1809264-A4 | ANTIMICROBIAL AMORPHOUS COMPOSITIONS | ACRYMED INC (US) | 2008-11-19 | — | — | EP | claimed |
| US-20080181951-A1 | Treatment of humans with colloidal silver composition | AMERICAN SILVER, LLC (US) | 2008-07-31 | — | — | US | claimed |
| WO-2008036787-A1 | ANTIMICROBIAL COMPOSITIONS CONTAINING GALLIUM | C.R. BARD, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| EP-1880213-A2 | SILVER/WATER, SILVER GELS AND SILVER-BASED COMPOSITIONS; AND METHODS FOR MAKING AND USING THE SAME | Holladay, Robert (US) | 2008-01-23 | — | — | EP | claimed |
| US-20070254044-A1 | Antimicrobial Amorphous Compositions | ACRYMED, INC. (US) | 2007-11-01 | — | — | US | claimed |
| EP-1809264-A2 | ANTIMICROBIAL AMORPHOUS COMPOSITIONS | ACRYMED, INC. (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1781098-A2 | ANTIMICROBIAL DEVICES AND COMPOSITIONS | ACRYMED, INC. (US) | 2007-05-09 | — | — | EP | claimed |
| WO-2006074117-A2 | SILVER/WATER, SILVER GELS AND SILVER-BASED COMPOSITIONS; AND METHODS FOR MAKING AND USING THE SAME | HOLLADAY ROBERT (US) | 2006-07-13 | — | — | WO | claimed |
| WO-2006034249-A2 | ANTIMICROBIAL AMORPHOUS COMPOSITIONS | ACRYMED, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| WO-2006015317-A2 | ANTIMICROBIAL DEVICES AND COMPOSITIONS | ACRYMED, INC. (US) | 2006-02-09 | — | — | WO | claimed |
| US-11939683-B2 | Method and system for production of antimicrobial disinfectant coatings using electrochemical synthesis | GORADIA PRERNA (IN) | 2024-03-26 | — | — | US | disclosed |
| WO-2000057933-A1 | TRICLOSAN AND SILVER COMPOUND CONTAINING MEDICAL DEVICES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AAAS, AOC1, COL14A1 | TDP1 4268/4885EYA2 4536/4885APP 867/4885 |
| US-20070254044-A1 | Antimicrobial Amorphous Compositions | CUTA, DSTN, NACA | TDP1 3296/4885EYA2 2259/4885APP 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.